Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation.

@article{Ozsahin2008LongtermOF,
  title={Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation.},
  author={Hulya Ozsahin and Marina Cavazzana‐Calvo and Luigi Daniele Notarangelo and Ansgar S. Schulz and Adrian J. Thrasher and Evelina Mazzolari and Mary A. Slatter and Françoise Le Deist and St{\'e}phane Blanche and Paul A. Veys and Anders Fasth and Robbert G M Bredius and Petr Sedlacek and Nico M. Wulffraat and Juan Ortega and Carsten Heilmann and Anne O’Meara and Jacek Wachowiak and Krzysztof Kałwak and Susanne Matthes-Martin and Tayfun Gungor and Aydan Ikinciogullari and Paul Landais and Andrew J. Cant and Wilhelm Friedrich and Alain Fischer},
  journal={Blood},
  year={2008},
  volume={111 1},
  pages={
          439-45
        }
}
Wiskott-Aldrich syndrome (WAS) is a rare X-linked immunodeficiency with microthrombocytopenia, eczema, recurrent infections, autoimmune disorders, and malignancies that are life-threatening in the majority of patients. In this long-term, retrospective, multicenter study, we analyzed events that occurred in 96 WAS patients who received transplants between 1979 and 2001 who survived at least 2 years following hematopoietic stem-cell transplantation (HSCT). Events included chronic graft-versus… 

Figures and Tables from this paper

Excellent Outcomes Following Hematopoietic Cell Transplantation for Wiskott-Aldrich Syndrome: A PIDTC Report.
TLDR
HCT outcomes for WAS have improved since 2005 compared to prior reports, and HCT at a younger age continues to be associated with superior outcomes supporting the recommendation for early HCT.
Case Report: Haploidentical Bone Marrow Transplantation in Two Brothers With Wiskott–Aldrich Syndrome Using Their Father as the Donor
TLDR
Two brothers who underwent successful T-cell replete haplo-BMT with PT-CY at ages 9 months and 4 years using their father as the donor were well-tolerated with minimal organ toxicity and no acute or chronic graft vs. host disease.
Transplantation of Hematopoietic Stem Cells for Primary Immunodeficiencies in Brazil: Challenges in Treating Rare Diseases in Developing Countries
TLDR
Although transplant for PID patients in Brazil has evolved since its beginning, it still faces some challenges like delayed diagnosis and referral, severe infections before transplant, a limited number of transplant centers with expertise, and resources for more advanced techniques.
Hematopoietic Stem Cell Therapy for Wiskott–Aldrich Syndrome: Improved Outcome and Quality of Life
TLDR
After trials and errors, inactivating lentiviral vectors carrying the WAS gene were successfully evaluated in clinical trials, demonstrating cure of the disease except for insufficient resolution of the platelet defect.
A risk factor analysis of outcomes after unrelated cord blood transplantation for children with Wiskott-Aldrich syndrome
TLDR
Umbilical cord blood transplantation is a good alternative option for young children with Wiskott-Aldrich syndrome lacking an HLA identical stem cell donor and overall survival tended to be better in patients transplanted after 2007.
Results and long-term outcome in 39 patients with Wiskott–Aldrich syndrome transplanted from HLA-matched and -mismatched donors
TLDR
An analysis in 39 WAS patients treated by hematopoietic stem cell transplantation (HSCT) in this center since 1983 suggests that HLA-nonidentical donor transplantation represents an alternative to be considered early in patients with severe disease.
Successful treatment of non‐Hodgkin's lymphoma using R‐CHOP in a patient with Wiskott–Aldrich syndrome followed by a reduced‐intensity stem cell transplant
TLDR
The case of a 17‐yr‐old boy with WAS who received an unrelated HSCT while in complete remission of diffuse large B‐cell lymphoma after chemotherapy, which resulted in rapid and stable engraftment and complete donor bone marrow chimerism one month after transplantation is reported.
Successful Unrelated Umbilical Cord Blood Stem Cell Transplantation for Wiskott-Aldrich Syndrome in 2 Cases Report
TLDR
The transplantation of umbilical cord blood stem cell from unrelated donor appears to be a feasible and effective strategy for further optimizing the outcome of HSCT for Wiskott-Aldrich syndrome.
...
...

References

SHOWING 1-10 OF 64 REFERENCES
Stem cell transplantation for the Wiskott–Aldrich syndrome: a single-center experience confirms efficacy of matched unrelated donor transplantation
TLDR
The safety and efficacy of MUD BMT when performed early in the clinical course of WAS is emphasized, further emphasizing the importance of closely matched unrelated donor bone marrow transplant in patients who lack an human leukocyte antigen-identical sibling.
Bone marrow transplantation for the Wiskott-Aldrich syndrome. Long-term follow-up.
TLDR
Seven of eight male patients who received bone marrow transplantation for the WAS have had excellent engraftment of their transplant and now have adequate lymphocyte and platelet function, which suggests that ablative preparative treatment followed by early bone marrow transplation from an HLA-matched donor is a highly successful therapy for this congenital disease.
Bone marrow transplantation (BMT) in Europe for primary immunodeficiencies other than severe combined immunodeficiency: a report from the European Group for BMT and the European Group for Immunodeficiency.
TLDR
Improvement in outcome was mainly because of a higher engraftment rate and a decrease in the frequency of infections, although Epstein-Barr virus-induced B-lymphocyte proliferative disorders occurred in 16 patients, although 10 of whom died.
Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program.
TLDR
The best transplantation outcomes in Wiskott-Aldrich syndrome are achieved with HLA-identical sibling donors, and equivalent survivals are possible with unrelated donors in young children.
Complete correction of the Wiskott-Aldrich syndrome by allogeneic bone-marrow transplantation.
TLDR
Two patients with the Wiskott-Aldrich syndrome had complete donor lymphoid and hematopoietic engraftment after successful allogeneic bone-marrow transplantation, which may be a model for the correction of other genetically determined immune and Hematologic bone- marrow disorders.
Reconstitution of normal megakaryocytopoiesis and immunologic functions in Wiskott-Aldrich syndrome by marrow transplantation following myeloablation and immunosuppression with busulfan and cyclophosphamide.
TLDR
The use of busulfan in moderate dosages as a myeloablative agent, coupled with cyclophosphamide, may offer an improved alternative to the use of lethal total body irradiation as a preparative regimen for complete correction of Wiskott-Aldrich syndrome by marrow transplantation.
...
...